Belgium· BE-AMP-SAM660815-00
Beyfortus 50 mg
A nirsevimab product containing nirsevimab, registered in Belgium by Sanofi Winthrop Industrie. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nirsevimab is registered in 14 of 19 countries.
Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Nirsevimab · ATC J06BD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nirsevimab
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Belgium (BE)
- ATC code
- J06BD08
- ATC class
- Nirsevimab
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb4802427EUR 613.86
- be_apb7740236
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirsevimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEYFORTUSSanofi Winthrop Industrie, Gentilly
- SpainBEYFORTUS 50 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
- SwitzerlandBeyfortus
- NorwayBeyfortusSanofi Winthrop Industrie
- PolandBeyfortusSanofi Winthrop Industrie
- SwedenBeyfortus 50 mg Injektionsvätska, lösning i förfylld sprutaSanofi Winthrop Industrie
- IcelandBeyfortusSanofi Winthrop Industrie
- United StatesBEYFORTUSSanofi Vaccines US Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beyfortus
- Liechtenstein · Beyfortus
- Norway · Beyfortus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e658c2b6-9813-4a66-a86a-a32f409eef48 GET /v1/drugs/e658c2b6-9813-4a66-a86a-a32f409eef48?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Beyfortus 50 mg",
"name_fr": "Beyfortus 50 mg",
"name_nl": "Beyfortus 50 mg",
"amp_code": "SAM660815-00",
"strengths": [
"100.0000",
"100.0000",
"100.0000"
],
"pack_count": 3,
"substances": [
"Nirsevimab",
"Arginine Hydrochloride",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nirsevimab",
"authorisation_numbers": [
"EU/1/22/1689/001",
"EU/1/22/1689/003",
"EU/1/22/1689/002"
]
}See everything about nirsevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.